Shares of Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $0.08 and traded as high as $0.0968. Inhibitor Therapeutics shares last traded at $0.0968, with a volume of 2,000 shares.
Inhibitor Therapeutics Stock Performance
The company has a market cap of $16.82 million, a P/E ratio of -9.68 and a beta of -0.67. The stock has a 50-day simple moving average of $0.09 and a 200 day simple moving average of $0.08.
About Inhibitor Therapeutics
Inhibitor Therapeutics, Inc (OTCMKTS:INTI) is a clinical-stage pharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s approach has centered on evaluating established compounds for potential use in oncology.
Its primary development program has involved itraconazole, an antifungal medication that is being investigated for potential anticancer applications. Inhibitor Therapeutics has studied itraconazole in connection with cancers including prostate cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Inhibitor Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
